Skip to content

Lung Cancer Health Center

Medical Reference Related to Lung Cancer

  1. Malignant Mesothelioma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - About This PDQ Summary

    Purpose of This SummaryThis PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of malignant mesothelioma. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.Reviewers and UpdatesThis summary is reviewed regularly and updated as necessary by the PDQ Adult Treatment Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH). Board members review recently published articles each month to determine whether an article should:be discussed at a meeting,be cited with text, orreplace or update an existing article that is already cited.Changes to the summaries are made through a consensus process

  2. Small Cell Lung Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Get More Information From NCI

    Call 1-800-4-CANCERFor more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time. A trained Cancer Information Specialist is available to answer your questions.Chat online The NCI's LiveHelp® online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer. Write to usFor more information from the NCI, please write to this address:NCI Public Inquiries Office9609 Medical Center Dr. Room 2E532 MSC 9760Bethesda, MD 20892-9760Search the NCI Web siteThe NCI Web site provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support

  3. Small Cell Lung Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Get More Information From NCI

    Call 1-800-4-CANCERFor more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time. A trained Cancer Information Specialist is available to answer your questions.Chat online The NCI's LiveHelp® online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer. Write to usFor more information from the NCI, please write to this address:NCI Public Inquiries Office9609 Medical Center Dr. Room 2E532 MSC 9760Bethesda, MD 20892-9760Search the NCI Web siteThe NCI Web site provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support

  4. Small Cell Lung Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - General Information About Small Cell Lung Cancer

    Some citations in the text of this section are followed by a level of evidence. The PDQ editorial boards use a formal ranking system to help the reader judge the strength of evidence linked to the reported results of a therapeutic strategy. (Refer to the PDQ summary on Levels of Evidence for more information.) Related Summaries Other PDQ summaries containing information related to lung cancer ...

  5. Malignant Mesothelioma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - nci_ncicdr0000062895-nci-header

    This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Malignant Mesothelioma Treatment

  6. Non-Small Cell Lung Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage 0 NSCLC Treatment

    Stage 0 NSCLC frequently progresses to invasive cancer.[1,2,3] Patients may be offered surveillance bronchoscopies and, if lesions are detected, potentially curative therapies.Standard Treatment Options for Stage 0 NSCLCStandard treatment options for stage 0 NSCLC include the following:Surgery.Endobronchial therapies, including photodynamic therapy, electrocautery, cryotherapy, and Nd-YAG laser therapy.SurgerySegmentectomy or wedge resection are used to preserve maximum normal pulmonary tissue since patients with stage 0 NSCLC are at a high risk for second lung cancers. Because these tumors are by definition noninvasive and incapable of metastasizing, they should be curable with surgical resection; however, such lesions, when identified, are often centrally located and may require a lobectomy. Endobronchial therapiesPatients with central lesions may be candidates for curative endobronchial therapy. Endobronchial therapies that preserve lung function include photodynamic therapy,

  7. Non-Small Cell Lung Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stages IIA and IIB NSCLC Treatment

    Standard Treatment Options for Stages IIA and IIB NSCLCStandard treatment options for stages IIA NSCLC and IIB NSCLC include the following:Surgery.Neoadjuvant chemotherapy.Adjuvant chemotherapy.Radiation therapy.Adjuvant radiation therapy has not been show to improve outcomes in patients with stages II NSCLC.SurgerySurgery is the treatment of choice for patients with stage II NSCLC. A lobectomy, pneumonectomy, or segmental resection, wedge resection, or sleeve resection may be performed as appropriate. Careful preoperative assessment of the patient's overall medical condition, especially the patient's pulmonary reserve, is critical in considering the benefits of surgery. Despite the immediate and age-related postoperative mortality rate, a 5% to 8% mortality rate with pneumonectomy or a 3% to 5% mortality rate with lobectomy can be expected. Evidence (surgery):The Cochrane Collaboration group reviewed 11 randomized trials with a total of

  8. Small Cell Lung Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Changes to This Summary (06 / 25 / 2013)

    The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above. Limited-Stage Small Cell Lung Cancer TreatmentAdded text as a list item to state that randomized trials have shown that doses higher than 25 Gy in 10 daily fractions do not improve long-term survival (cited Le Péchoux et al. and Wolfson et al. as references 32 and 33, respectively).This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.

  9. Small Cell Lung Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Extensive-Stage Small Cell Lung Cancer Treatment

    Standard Treatment Options for Patients With Extensive-Stage Small Cell Lung Cancer (SCLC)Standard treatment options for patients with extensive-stage SCLC include the following:Combination chemotherapy.Radiation therapy.Prophylactic cranial irradiation.Combination chemotherapyChemotherapy for patients with extensive-stage disease (ED) SCLC is commonly given as a two-drug combination of platinum and etoposide in doses associated with at least moderate toxic effects (as in limited-stage [LD] SCLC).[1] Cisplatin is associated with significant toxic effects and requires fluid hydration, which can be problematic in patients with cardiovascular disease. Carboplatin is active in SCLC, is dosed according to renal function, and is associated with less nonhematological toxic effects.Other regimens appear to produce similar survival outcomes but have been studied less extensively or are in less common use.Table 2. . Combination Chemotherapy For Extensive-Stage Small Cell

  10. Non-Small Cell Lung Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - General Information About Non-Small Cell Lung Cancer (NSCLC)

    NSCLC is any type of epithelial lung cancer other than small cell lung cancer (SCLC). The most common types of NSCLC are squamous cell carcinoma,large cell carcinoma,and adenocarcinoma,but there are several other types that occur less frequently,and all types can occur in unusual histologic variants. Although NSCLCs are associated with cigarette smoke,adenocarcinomas may be found in ...

Displaying 61 - 70 of 208 Articles << Prev Page 3 4 5 6 7 8 9 10 11 12 Next >>

Today on WebMD

Broken cigarette
Do you know the myths from the facts?
man with a doctor
Our health check will steer you in the right direction.
 
sauteed cherry tomatoes
Fight cancer one plate at a time.
Lung cancer xray
See it in pictures, plus read the facts.
 
15 Cancer Symptoms Men Ignore
FEATURE
Lung Cancer Risks Myths and Facts
SLIDESHOW
 
cancer fighting foods
SLIDESHOW
Improving Lung Cancer Survival Targeted Therapy
VIDEO
 
Lung Cancer Surprising Differences Between Sexes
VIDEO
Pets Improve Your Health
SLIDESHOW
 
Vitamin D
SLIDESHOW
Lung Cancer Surgery Options
VIDEO
 

WebMD Special Sections